Clinical Accelerator

Clinical Accelerator

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Clinical Accelerator is a lean, execution-focused CRO built to address the unique challenges of early-stage medical device trials. Founded with academic roots, the company combines deep clinical and regulatory expertise with a proven network of high-performing sites to accelerate the clinical development of breakthrough technologies. It has successfully supported over 100 MedTech clients globally, offering a flat operational structure for direct sponsor access and accountability, with a mission to turn innovative ideas into robust clinical evidence efficiently.

CardiovascularOncologyStructural Heart Disease

Technology Platform

Operational platform for early-stage medical device trials, featuring a sponsor-aligned CRO model, a dedicated site network in Eastern Europe/Central Asia, and an integrated SMPEO (Site Management, Patient Enrollment, and Operations) approach for predictable execution.

Funding History

2
Total raised:$10M
Series A$8M
Grant$2M

Opportunities

Growth is fueled by the expanding global MedTech innovation sector and the increasing trend towards decentralized clinical trials in strategic regions.
Opportunities exist to become the preferred early-stage CRO for venture-backed device companies and to expand service offerings into adjacent areas like regulatory strategy for its core geographic regions.

Risk Factors

Key risks include geographic concentration in Eastern Europe/Central Asia, dependency on the funding climate for early-stage MedTech clients, and the constant need to maintain flawless execution to protect its reputation in a high-stakes niche.

Competitive Landscape

Competes against large, full-service CROs (less agile for early studies) and other specialized device CROs. Differentiates through an exclusive FIH/EFS focus, a flat, sponsor-aligned operational model, and a strategically built site network in regions offering regulatory and recruitment advantages for early-stage trials.